据路透报道,癌症测试制造商精密科学公司(EXAS)周一盘后重挫28.16%,收于52美元。公司下调2024年全年收入指引,引发市场对其未来收入增长前景的担忧。
精密科学公司将2024年全年收入预期从之前的28.1亿美元至28.5亿美元,下调至27.3亿美元至27.5亿美元。公司还将筛选部门的收入指引从之前的21.6亿美元至21.8亿美元,下调至20.8亿美元至21亿美元。
公司表示,第三季度实际营收7.09亿美元,低于预期的7.177亿美元。公司CEO表示,"我们在第三季度的执行情况和更新的全年展望没有反映出我们的全部潜力。"但他强调公司计划在2025年加速增长,长期前景依旧强劲。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.